

M45-A
Vol. 26 No. 19
Replaces M45-P
Vol. 25 No. 26

Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline

This document provides guidance to clinical microbiology laboratories for standardized susceptibility testing of infrequently isolated or fastidious bacteria that are not presently included in CLSI/NCCLS documents M2, M7, or M11. The tabular information in this document presents the most current information for drug selection, interpretation, and quality control for the infrequently isolated or fastidious bacterial pathogens included in this guideline.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.



(Formerly NCCLS)

Clinical and Laboratory Standards Institute

Advancing Quality in Healthcare Testing

Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) is an international, interdisciplinary, nonprofit, standards-developing, and educational organization that promotes the development and use of voluntary consensus standards and guidelines within the healthcare community. It is recognized worldwide for the application of its unique consensus process in the development of standards and guidelines for patient testing and related healthcare issues. Our process is based on the principle that consensus is an effective and cost-effective way to improve patient testing and healthcare services.

In addition to developing and promoting the use of voluntary consensus standards and guidelines, we provide an open and unbiased forum to address critical issues affecting the quality of patient testing and health care.

PUBLICATIONS

A document is published as a standard, guideline, or committee report.

Standard A document developed through the consensus process that clearly identifies specific, essential requirements for materials, methods, or practices for use in an unmodified form. A standard may, in addition, contain discretionary elements, which are clearly identified.

Guideline A document developed through the consensus process describing criteria for a general operating practice, procedure, or material for voluntary use. A guideline may be used as written or modified by the user to fit specific needs.

Report A document that has not been subjected to consensus review and is released by the Board of Directors.

CONSENSUS PROCESS

The CLSI voluntary consensus process is a protocol establishing formal criteria for:

- the authorization of a project
- the development and open review of documents
- the revision of documents in response to comments by users
- the acceptance of a document as a consensus standard or guideline.

Most documents are subject to two levels of consensus—"proposed" and "approved." Depending on the need for field evaluation or data collection, documents may also be made available for review at an intermediate consensus level.

Proposed A consensus document undergoes the first stage of review by the healthcare community as a proposed standard or guideline. The document should receive a wide and thorough technical review, including an overall review of its scope, approach, and utility, and a line-by-line review of its technical and editorial content.

Approved An approved standard or guideline has achieved consensus within the healthcare community. It should be reviewed to assess the utility of the final document, to ensure attainment of consensus (i.e., that comments on earlier versions have been satisfactorily addressed), and to identify the need for additional consensus documents.

Our standards and guidelines represent a consensus opinion on good practices and reflect the substantial agreement by materially affected, competent, and interested parties obtained by following CLSI's established consensus procedures. Provisions in CLSI standards and guidelines may be more or less stringent than applicable regulations. Consequently, conformance to this voluntary consensus document does not relieve the user of responsibility for compliance with applicable regulations.

COMMENTS

The comments of users are essential to the consensus process. Anyone may submit a comment, and all comments are addressed, according to the consensus process, by the committee that wrote the document. All comments, including those that result in a change to the document when published at the next consensus level and those that do not result in a change, are responded to by the committee in an appendix to the document. Readers are strongly encouraged to comment in any form and at any time on any document. Address comments to Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, PA 19087, USA.

VOLUNTEER PARTICIPATION

Healthcare professionals in all specialties are urged to volunteer for participation in CLSI projects. Please contact us at customerservice@clsi.org or +610.688.0100 for additional information on committee participation.

M45-A

ISBN 1-56238-607-7

Volume 26 Number 19

ISSN 0273-3099

Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline

James H. Jorgensen, PhD
Janet Hindler, MCLS, MT(ASCP)
Diane M. Citron, M(ASCP)
Franklin R. Cockerill, III, MD
Thomas R. Fritsche, PhD, MD
Guido Funke, MD

Jean B. Patel, PhD, D(ABMM)
Paul C. Schreckenberger, PhD, D(ABMM)
John D. Turnidge, MD
Robert D. Walker, PhD
David F. Welch, PhD, D(ABMM)

Abstract

If the susceptibility of a bacterial pathogen to antimicrobial agents cannot be predicted based on the identity of the organism alone, *in vitro* antimicrobial susceptibility testing of the organism isolated from the disease processes is indicated. Susceptibility testing is particularly necessary in those situations where the etiologic agent belongs to a bacterial species for which resistance to commonly used antimicrobial agents has been documented, or could arise.

A variety of laboratory techniques can be used to measure the *in vitro* susceptibility of bacteria to antimicrobial agents. This document describes the standard microdilution and agar disk diffusion methods. It also includes a series of procedures designed to standardize test performance. The performance, applications, and limitations of the current CLSI-recommended methods are described.

The tabular information in this document presents the most current information for drug selection, interpretation, and quality control for the infrequently isolated or fastidious bacterial pathogens included in this guideline. As more information becomes available, changes will be incorporated into future revisions of this document.

Clinical and Laboratory Standards Institute (CLSI). *Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline*. CLSI document M45-A (ISBN 1-56238-607-7). Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2006.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the healthcare community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI/NCCLS documents. Current editions are listed in the CLSI catalog, which is distributed to member organizations, and to nonmembers on request. If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org



(Formerly NCCLS)

This publication is protected by copyright. No part of it may be reproduced, stored in a retrieval system, transmitted, or made available in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without prior written permission from Clinical and Laboratory Standards Institute, except as stated below.

Clinical and Laboratory Standards Institute hereby grants permission to reproduce limited portions of this publication for use in laboratory procedure manuals at a single site, for interlibrary loan, or for use in educational programs provided that multiple copies of such reproduction shall include the following notice, be distributed without charge, and, in no event, contain more than 20% of the document's text.

Reproduced with permission, from CLSI publication M45-A—*Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline* (ISBN 1-56238-607-7). Copies of the current edition may be obtained from Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

Permission to reproduce or otherwise use the text of this document to an extent that exceeds the exemptions granted here or under the Copyright Law must be obtained from Clinical and Laboratory Standards Institute by written request. To request such permission, address inquiries to the Executive Vice President, Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

Copyright ©2006. Clinical and Laboratory Standards Institute.

Suggested Citation

(Clinical and Laboratory Standards Institute. *Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline*. CLSI document M45-A [ISBN 1-56238-607-7]. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2006.)

Proposed Guideline

October 2005

Approved Guideline

May 2006

ISBN 1-56238-607-7
ISSN 0273-3099

Committee Membership

Area Committee on Microbiology

Mary Jane Ferraro, PhD, MPH
Chairholder
Massachusetts General Hospital
Boston, Massachusetts

James H. Jorgensen, PhD
Vice-Chairholder
University of Texas Health Science
Center
San Antonio, Texas

Donald R. Callihan, PhD
BD Diagnostic Systems
Sparks, Maryland

Freddie Mae Poole
FDA Center for Devices and
Radiological Health
Rockville, Maryland

David L. Sewell, PhD
Veterans Affairs Medical Center
Portland, Oregon

Thomas R. Shryock, PhD
Elanco Animal Health
Greenfield, Indiana

Jana M. Swenson, MMSc
Centers for Disease Control and
Prevention
Atlanta, Georgia

Michael L. Wilson, MD
Denver Health Medical Center
Denver, Colorado

Advisors

Ellen Jo Baron, PhD
Stanford Univ. Hospital & Medical
School
Stanford, California

Lynne S. Garcia, MS
LSG & Associates
Santa Monica, California

Richard L. Hodinka, PhD
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

Michael A. Pfaller, MD
University of Iowa College of Medicine
Iowa City, Iowa

Robert P. Rennie, PhD
University of Alberta Hospital
Edmonton, Alberta, Canada

John H. Rex, MD, FACP
AstraZeneca
Cheshire, United Kingdom

Melvin P. Weinstein, MD
Robert Wood Johnson Medical School
New Brunswick, New Jersey

Matthew A. Wikler, MD, MBA, FIDSA
Mpex Pharmaceuticals, Inc.
San Diego, California

Gail L. Woods, MD
University of Arkansas for Medical
Sciences
Little Rock, Arkansas

Subcommittee on Antimicrobial Susceptibility Testing

Matthew A. Wikler, MD, MBA, FIDSA
Chairholder
Mpex Pharmaceuticals
San Diego, California

Franklin R. Cockerill, III, MD
Mayo Clinic/Mayo Foundation
Rochester, Minnesota

William A. Craig, MD
University of Wisconsin
Madison, Wisconsin

Michael N. Dudley, PharmD
Mpex Pharmaceuticals
San Diego, California

George M. Eliopoulos, MD
Beth Israel Deaconess Medical Center
Boston, Massachusetts

David W. Hecht, MD
Loyola University Medical Center
Maywood, Illinois

Janet F. Hindler, MCLS, MT(ASCP)
UCLA Medical Center
Los Angeles, California

Donald E. Low, MD
Mount Sinai Hospital
Toronto, Ontario, Canada

Daniel J. Sheehan, PhD
Pfizer Inc.
New York, New York

Fred C. Tenover, PhD, ABMM
Centers for Disease Control and
Prevention
Atlanta, Georgia

John D. Turnidge, MD
Women's and Children's Hospital
North Adelaide, Australia

Melvin P. Weinstein, MD
Robert Wood Johnson Medical School
New Brunswick, New Jersey

Barbara L. Zimmer, PhD
Dade Behring MicroScan
West Sacramento, California

Advisors

Patricia A. Bradford, PhD
Wyeth Research
Pearl River, New York

John S. Bradley, MD
Children's Hospital and Health Center
San Diego, California

Steven D. Brown, PhD
The Clinical Microbiology Institute
Wilsonville, Oregon

Karen Bush, PhD
Johnson & Johnson Pharmaceutical
Research and Development, L.L.C.
Raritan, New Jersey

Prof. José María Casellas
Universidad Nacional de Rosario
Victoria, Argentina

Edward M. Cox, Jr., MD, MPH
FDA Center for Drug Evaluation and
Research
Rockville, Maryland

Lawrence V. Friedrich, PharmD
Cubist Pharmaceuticals
Mt. Pleasant, South Carolina

Mark J. Goldberger, MD, MPH
FDA Center for Drug Evaluation and
Research
Rockville, Maryland

Dwight J. Hardy, PhD
University of Rochester Medical Center
Rochester, New York

Yoichi Hirakata, MD, PhD
Nagasaki University School of
Medicine and Dentistry
Nagasaki, Japan

Ronald N. Jones, MD
JMI Laboratories
North Liberty, Iowa

Gunnar Kahlmeter, MD, PhD
ESCMID
Växjö, Sweden

Advisors (Continued)

Frederic J. Marsik, PhD, ABMM
FDA Center for Drug Evaluation and
Research
Rockville, Maryland

John E. McGowan, Jr., MD
Emory University, Rollins School of
Public Health
Atlanta, Georgia

Linda A. Miller, PhD
GlaxoSmithKline
Collegeville, Pennsylvania

Mary R. Motyl, PhD, D(ABMM)
Merck & Company, Inc.
Rahway, New Jersey

Susan D. Munro, MT(ASCP)
Stanford Hospital and Clinics
Stanford, California

Charles H. Nightingale, PhD
Hartford Hospital
Hartford, Connecticut

Jean B. Patel, PhD, D(ABMM)
Centers for Disease Control and
Prevention
Atlanta, Georgia

David Paterson, MD
University of Pittsburgh
Pittsburgh, Pennsylvania

John H. Powers, III, MD, FACP
FDA Center for Drug Evaluation and
Research
Rockville, Maryland

L. Barth Reller, MD
Duke University Medical Center
Durham, North Carolina

Daniel F. Sahn, PhD
Focus Bio-Inova, Inc.
Herndon, Virginia

Dale A. Schwab, PhD, D(ABMM)
Quest Diagnostics, Nichols Institute
San Juan Capistrano, California

Sally Selepak, MT(ASCP)
FDA Center for Devices and
Radiological Health
Rockville, Maryland

Jana M. Swenson, MMSc
Centers for Disease Control and
Prevention
Atlanta, Georgia

George H. Talbot, MD
Talbot Advisors LLC
Wayne, Pennsylvania

Working Group on Susceptibility Testing of Infrequently Encountered or Fastidious Bacteria

James H. Jorgensen, PhD
Chairholder
University of Texas Health Science Ctr.
San Antonio, Texas

Janet F. Hindler, MCLS, MT(ASCP)
Vice-Chairholder
UCLA Medical Center
Los Angeles, California

Diane M. Citron, M(ASCP)
Santa Monica – UCLA Medical Center
R.M. Alden Research Laboratory
Santa Monica, California

Franklin R. Cockerill, III, MD
Mayo Clinic/Mayo Foundation
Rochester, Minnesota

Thomas R. Fritsche, PhD, MD
JMI Laboratories
North Liberty, Iowa

Guido Funke, MD
Gartner & Colleagues Laboratories
Ravensburg, Germany

Jean B. Patel, PhD, D(ABMM)
Centers for Disease Control and Prevention
Atlanta, Georgia

Paul C. Schreckenberger, PhD,
D(ABMM)
Loyola University Medical Center
Maywood, Illinois

John D. Turnidge, MD
Women's and Children's Hospital
North Adelaide, Australia

Robert D. Walker, PhD
FDA Center for Veterinary Medicine
Laurel, Maryland

David F. Welch, PhD, D(ABMM)
University of Texas Southwestern Medical
Center
Dallas, Texas

Advisors

Paul G. Ambrose, PharmD
Institute for Clinical Pharmacodynamics
Ordway Research Institute
Albany, New York

Anton F. Ehrhardt, PhD
Cubist Pharmaceuticals
Lexington, Massachusetts

Frederic J. Marsik, PhD, ABMM
FDA Center for Drug Evaluation and Research
Rockville, Maryland

Patrick McDermott, PhD
FDA Center for Veterinary Medicine
Laurel, Maryland

Jana M. Swenson, MMSc
Centers for Disease Control and Prevention
Atlanta, Georgia

Fred C. Tenover, PhD, ABMM
Centers for Disease Control and
Prevention
Atlanta, Georgia

Mary K. York, PhD, ABMM
MKY Microbiology Consulting
Walnut Creek, California

Staff

Clinical and Laboratory Standards
Institute
Wayne, Pennsylvania

John J. Zlockie, MBA
Vice President, Standards

Tracy A. Dooley, BS, MLT(ASCP)
Staff Liaison

Donna M. Wilhelm
Editor

Melissa A. Lewis
Assistant Editor

Contents

Abstract i

Committee Membership iii

Foreword ix

1 Scope 1

2 Introduction 1

3 Standard Precautions 4

4 Definitions 4

5 Indications for Performing Susceptibility Tests 4

6 Methods for Dilution Antimicrobial Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria 5

 6.1 Selection of Antimicrobial Agents 5

 6.2 Antimicrobial Agents 5

 6.3 Interpretive Categories 5

7 Methods for Antimicrobial Disk Diffusion Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria 6

8 Therapy-Related Comments 6

9 Quality Control 6

 9.1 Minimum Laboratory Requirements for Testing Infrequently Isolated or Fastidious Bacteria 7

10 Detection of Resistance to Some β -Lactams by a Direct β -Lactamase Test 7

References 8

Table 1. *Abiotrophia* species and *Granulicatella* species (Formerly Known as Nutritionally Deficient or Nutritionally Variant Streptococci)—Information and Interpretive Criteria for Broth Microdilution Susceptibility Testing 10

Table 2. *Aeromonas hydrophila* Complex (Includes *A. caviae*, *A. hydrophila*, *A. jandaei*, *A. schubertii*, and *A. veronii*, Two Biotypes) and *Plesiomonas shigelloides*—Information and Interpretive Criteria for Broth Microdilution and Disk Diffusion Susceptibility Testing 12

Table 3. *Bacillus* species (Not *B. anthracis*)—Information and Interpretive Criteria for Broth Microdilution Susceptibility Testing 14

Table 4. *Campylobacter jejuni/coli*—Information and Interpretive Criteria for Broth Microdilution and Disk Diffusion Susceptibility Testing 16

Table 5. *Corynebacterium* species (Including *C. diphtheriae*)—Information and Interpretive Criteria for Broth Microdilution Susceptibility Testing 18

Contents (Continued)

Table 6. *Erysipelothrix rhusiopathiae*—Information and Interpretive Criteria for Broth Microdilution Susceptibility Testing.....20

Table 7. HACEK Group: the Aphrophilus Cluster of the Genus *Haemophilus* (i.e., *H. aphrophilus*, *H. paraphrophilus*, *H. segnis*), *Actinobacillus actinomycetemcomitans*, *Cardiobacterium* species, *Eikenella corrodens*, and *Kingella* species—Information and Interpretive Criteria for Broth Microdilution Susceptibility Testing22

Table 8. *Lactobacillus* species—Information and Interpretive Criteria for Broth Microdilution Susceptibility Testing.....24

Table 9. *Leuconostoc* species—Information and Interpretive Criteria for Broth Microdilution Susceptibility Testing.....26

Table 10. *Listeria monocytogenes*—Information and Interpretive Criteria for Broth Microdilution Susceptibility Testing.....27

Table 11. *Moraxella catarrhalis*—Information and Interpretive Criteria for Broth Microdilution Susceptibility Testing.....28

Table 12. *Pasteurella* species—Information and Interpretive Criteria for Broth Microdilution and Disk Diffusion Susceptibility Testing.....30

Table 13. *Pediococcus* species—Information and Interpretive Criteria for Broth Microdilution Susceptibility Testing.....32

Table 14. *Vibrio* species (Not *V. cholerae*)—Information and Interpretive Criteria for Broth Microdilution and Disk Diffusion Susceptibility Testing.....34

Table 15. Summary of Testing Conditions and QC Recommendations for Infrequently Isolated or Fastidious Bacteria.....36

Table 16. Acceptable Limits for Quality Control Strains Used to Monitor Accuracy of Minimal Inhibitory Concentrations (MICs) ($\mu\text{g/mL}$) of Nonfastidious Organisms (Using Cation-Adjusted Mueller-Hinton Medium Without Blood or Other Supplements).....37

Table 16A. Acceptable Limits for *Streptococcus pneumoniae* ATCC® 49619 Used to Monitor Accuracy of Minimal Inhibitory Concentrations (MICs) ($\mu\text{g/mL}$) (Using Cation-Adjusted Mueller-Hinton Broth With Lysed Horse Blood [2.5 to 5% v/v]).....38

Table 16B. Acceptable Limits for Quality Control Strains Used to Monitor Accuracy of Broth Microdilution Minimal Inhibitory Concentrations (MICs) ($\mu\text{g/mL}$) of *Campylobacter jejuni* ATCC® 33560 (Using Cation-Adjusted Mueller-Hinton Broth With Lysed Horse Blood [2.5 to 5% v/v]).....39

Table 17. Acceptable Limits for Quality Control Strains Used to Monitor Accuracy of Disk Diffusion Testing of Nonfastidious Organisms (Using Mueller-Hinton Medium Without Blood or Other Supplements)40

Table 17A. Acceptable Limits for *Streptococcus pneumoniae* ATCC® 49619 Used to Monitor Accuracy of Disk Diffusion Testing41

Glossary I (Part 1). β -lactams: Class and Subclass Designation and Generic Name.....42

Contents (Continued)

Glossary I (Part 2). Non-β-lactams: Class and Subclass Designation and Generic Name43

Glossary II. Abbreviations/Routes of Administration/Drug Class for Antimicrobial Agents Listed
in CLSI Document M100.....44

Additional References.....47

Summary of Consensus Comments and Committee Responses57

The Quality System Approach.....60

Related CLSI/NCCLS Publications61

Foreword

This document was developed for the purpose of providing guidance to clinical microbiology laboratories regarding the performance of standardized susceptibility testing, when needed, of infrequently isolated or fastidious bacteria that are not presently included in the most current editions of CLSI/NCCLS documents M2—*Performance Standards for Antimicrobial Disk Susceptibility Tests*, M7—*Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically*, or M11—*Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria*. Some of the organisms included herein are aerobic gram-negative bacilli that are not members of the family *Enterobacteriaceae*, but may be tested by the standard CLSI broth microdilution or disk diffusion methods in the same manner as the much more common *Enterobacteriaceae* isolates. Some aerobic gram-positive cocci and bacilli that are encountered periodically by clinical laboratories can likewise be tested reliably by the standard CLSI MIC or disk diffusion test methods in a manner analogous to *Staphylococcus* or *Enterococcus* spp. In addition, several genera of fastidious gram-positive and gram-negative bacteria can be tested in the same manner as the streptococci, using blood-supplemented Mueller-Hinton media. For the purpose of this document, the term *fastidious* is used to describe bacteria that require media supplemented with blood or blood components and that possibly need an atmosphere other than ambient air (e.g., with 5% CO₂) for acceptable growth. Because the standard CLSI media, reagents, and procedures can be used to test the organisms included in this guideline, the quality control procedures, strains, and acceptable zone diameter and MIC limits that have been established through previous rigorous studies can be utilized for tests with the less common organisms that are included in this document. The working group used a thorough search of the published literature in conjunction with the clinical experience of the members to apply or adapt interpretive criteria or breakpoints from other organisms that could best be applied to the interpretation of tests of the less common organisms in this document. Users of the guideline should be aware that the very extensive microbiological, clinical, and pharmacodynamic databases normally employed for setting breakpoints by CLSI did not exist for the collection of “orphan” organisms described in this document.

It is important for users of M45-A to recognize that commercial susceptibility testing devices are not addressed in this guideline. The methods described herein are generic reference procedures that can be used for routine susceptibility testing by clinical laboratories, or that can be used by clinical laboratories to evaluate commercial devices for possible routine use. Results generated by the CLSI reference methods are used by the United States Food and Drug Administration to evaluate the performance of commercial systems before clearance is given for marketing in the United States. Clearance by the FDA indicates that the agency concludes that commercial devices provide susceptibility results that are substantially equivalent to results generated using the CLSI reference methods for the organisms and antimicrobial agents described in the manufacturer’s approved package insert. Some laboratories could find that a commercial dilution, antibiotic gradient, colorimetric, turbidimetric, fluorometric, or other method is suitable for selective or routine use.

Key Words

Agar dilution, antimicrobial agent, antimicrobial susceptibility, broth dilution, disk diffusion, microdilution, minimal inhibitory concentration (MIC), susceptibility testing

CLSI Subcommittee on Antimicrobial Susceptibility Testing Mission Statement

The CLSI Subcommittee on Antimicrobial Susceptibility Testing is composed of representatives from the professions, government, and industry, including microbiology laboratories, government agencies, healthcare providers and educators, and pharmaceutical and diagnostic microbiology industries. Using the CLSI voluntary consensus process, the subcommittee develops standards that promote accurate antimicrobial susceptibility testing and appropriate reporting.

The mission of the CLSI Subcommittee on Antimicrobial Susceptibility Testing is to:

- develop standard reference methods for antimicrobial susceptibility tests;
- provide quality control parameters for standard test methods;
- establish interpretive criteria for the results of standard antimicrobial susceptibility tests;
- provide suggestions for testing and reporting strategies that are clinically relevant and cost-effective;
- continually refine standards and optimize the detection of emerging resistance mechanisms through the development of new or revised methods, interpretive criteria, and quality control parameters;
- educate users through multimedia communication of standards and guidelines; and
- foster a dialogue with users of these methods and those who apply them.

The ultimate purpose of the subcommittee's mission is to provide useful information to enable laboratories to assist the clinician in the selection of appropriate antimicrobial therapy for patient care. The standards and guidelines are meant to be comprehensive and to include all antimicrobial agents for which the data meet established CLSI guidelines. The values that guide this mission are quality, accuracy, fairness, timeliness, teamwork, consensus, and trust.

Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline

1 Scope

CLSI documents M2—*Performance Standards for Antimicrobial Disk Susceptibility Tests* and M7—*Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically* describe standardized methods for antimicrobial susceptibility testing of common aerobic bacteria, including some fastidious organisms or potential agents of bioterrorism. However, there are a number of less frequently encountered or fastidious bacteria that are not addressed in M2, M7, and M100—*Performance Standards for Antimicrobial Susceptibility Testing*. Some of these are organisms that may cause serious infections (e.g., infective endocarditis), infections associated with trauma and environmental contamination, or device-associated infections in immunocompromised or postsurgical patients (e.g., intravascular catheters, implanted devices, central nervous system shunts). Key gram-positive organisms include *Corynebacterium* spp., *Bacillus* spp. (not *B. anthracis*), and several genera that have intrinsic vancomycin resistance. Nonfastidious gram-negative bacteria include *Aeromonas* spp., *Plesiomonas* spp., *Vibrio* spp., and *Moraxella catarrhalis*.

The fastidious gram-negative bacilli include the HACEK group, *Campylobacter*, and *Pasteurella* spp. Organisms considered to be members of the HACEK group are the Aphrophilus cluster of the genus *Haemophilus* (i.e., *H. aphrophilus*, *H. paraphrophilus*, *H. segnis*), *Actinobacillus actinomycetemcomitans*, *Cardiobacterium* spp., *Eikenella corrodens*, and *Kingella* spp. *Capnocytophaga* spp. are outside the scope of this document because of the lack of suitable methods for broth dilution or disk diffusion susceptibility testing. The *Capnocytophaga* spp. frequently produce β -lactamase, but they are generally susceptible to β -lactam/ β -lactamase inhibitor combinations, clindamycin, imipenem, and linezolid.

Fastidious gram-positive bacteria that may cause endocarditis include *Abiotrophia* spp. and *Granulicatella* spp. Acquired antimicrobial resistance mechanisms have been reported in many of these organisms, and the medical literature includes descriptions of susceptibility results derived from use of standard CLSI methods or certain nonstandard procedures.

Because infections due to organisms addressed in M45 occur less frequently than many of the organisms presently covered in CLSI documents M2 and M7, and the fact that many of the antimicrobial agents of interest have been marketed for a number of years, it is not reasonable to expect the intensive CLSI/NCCLS document M23-specified studies (*Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters*) to be conducted on this special group of organisms. Instead, the goal of this document is to propose test conditions and interpretive criteria based upon a careful review of published microbiological data (distributions of MICs), and the extant clinical literature regarding therapy for these organisms, and in a few instances, a review of existing pharmacokinetic data on the drugs of interest. In some cases, limited *in vitro* testing was performed. It is hoped that this CLSI guideline will assist clinical microbiology laboratories in determining an approach for testing these unusual organisms that is relevant to their individual practice settings.

2 Introduction

CLSI documents M2 and M7 describe reference and standardized methods for antimicrobial susceptibility testing of common, rapidly growing aerobic bacteria, including staphylococci, enterococci, members of the *Enterobacteriaceae*, *Pseudomonas* spp., and *Acinetobacter* spp., *Burkholderia cepacia*, and *Stenotrophomonas maltophilia* (in addition to a few other nonglucose-fermentative gram-negative bacilli). These documents also include standard susceptibility testing methods, quality control values, and specific breakpoints for several fastidious bacterial species, including *Haemophilus influenzae*, *Neisseria*